Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)

Trial Profile

A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs APL 2 (Primary)
  • Indications Glomerulonephritis; IgA nephropathy; Kidney disorders; Lupus nephritis; Membranoproliferative glomerulonephritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 11 Jan 2019 Planned End Date changed from 22 Oct 2019 to 22 Jun 2020.
    • 11 Jan 2019 Planned primary completion date changed from 22 Jul 2019 to 22 Dec 2019.
    • 13 Nov 2018 According to an Apellis Pharmaceuticals media release, the company expects the data from the trial in 2019. The trial timeline has been updated from a four month data readout to a one year data readout.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top